SCHEMBL3015221

SCHEMBL3015221

COc1ccc(OC)c(-c2csc(N3CCC(S(=O)(=O)c4ccc(F)cc4Cl)CC3)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.49
REV1 Q9UBZ9 1/20 0.47
CTSS P25774 4/20 0.46
MAPT P10636 4/20 0.46
USP2 O75604 1/20 0.46
RECQL P46063 1/20 0.46
HSD17B10 Q99714 1/20 0.46
LMNA P02545 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
KMT2A Q03164 3/20 0.43
NPC1 O15118 2/20 0.43
MEN1 O00255 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
RAB9A P51151 2/20 0.42
TP53 P04637 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010824 0.93 AR (0.56) ARREV1CTSSMAPTUSP2
SCHEMBL3019238 0.92 AR (0.51) ARREV1MAPTUSP2RECQL
SCHEMBL3013192 0.92 REV1 (0.49) ARREV1MAPTUSP2RECQL
SCHEMBL3017347 0.91 AR (0.54) ARREV1CTSSMAPTUSP2
SCHEMBL3011933 0.90 REV1 (0.47) ARREV1MAPTUSP2RECQL
SCHEMBL3010453 0.89 AR (0.50) ARREV1MAPTUSP2RECQL
SCHEMBL3019749 0.89 REV1 (0.51) ARREV1CTSSMAPTUSP2
SCHEMBL3013197 0.88 RAB9A (0.54) ARCTSSMAPTUSP2RECQL
SCHEMBL3007727 0.88 REV1 (0.53) ARREV1MAPTUSP2RECQL
SCHEMBL3011923 0.87 REV1 (0.48) ARREV1MAPTUSP2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885REV1 4692/4885CTSS 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.